Speciality: Pediatrics
Description:
A warm welcome to all the medical professionals in this interesting session on Arthritis and children: What is JIA?
Juvenile idiopathic arthritis (JIA) is the most common type of arthritis affecting children and adolescents under the age of 16. It is an autoimmune condition in which the body’s immune system mistakenly attacks its own tissues, leading to inflammation in the joints. This results in symptoms such as joint pain, swelling, stiffness, and reduced mobility. JIA can affect one or multiple joints and, in some cases, may also involve other organs, such as the eyes or skin.
There are several subtypes of JIA, each with different characteristics and levels of severity. While the exact cause is unknown, a combination of genetic and environmental factors is believed to play a role. Early diagnosis and treatment are crucial in managing JIA, as they can prevent long-term joint damage and improve the child’s quality of life. Treatment typically includes medications like NSAIDs, DMARDs, or biologics, along with physical therapy to maintain joint function and mobility.
Therefore, get an overall knowledge of arthritis and children: what is JIA?
See More Webinars @ Hidoc Webinars
1.
Parkinson patient's gait is restored by a spinal cord stimulator.
2.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
3.
Next Day Mood Is Affected by Ability to Recover From Work.
4.
Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness
5.
Children with cancer experience much less pain at home when using a pain monitoring app.
1.
Unlocking the Potential of Leukemia Treatment: A New Hope for Patients
2.
Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology
3.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
4.
The Lowdown on Darbepoetin: Understanding Its Uses and Side Effects
5.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation